Evidence map›Paper›PMID 34307141›Full record

ArticleFrontiers in oncology2021

The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study.

Jason C Hsu, Phung-Anh Nguyen, Yen-Tzu Chen, Szu-Chun Yang, Chien-Chung Lin, Yi-Hsin Yang, Yu-Chao Lin, Te-Chun Hsia, Hsing-Chun Hsieh, Jia-Syuan Wu and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 2 countries.

Jason C HsuInternational Ph.D. Program in Biotech and Healthcare Management, College of Management, Taipei Medical University, Taipei, Taiwan.
Phung-Anh NguyenInternational Center for Health Information Technology, College of Medical Science & Technology, Taipei Medical University, Taipei, Taiwan.
Yen-Tzu ChenSchool of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Szu-Chun YangDepartment of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Chien-Chung LinDepartment of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Yi-Hsin YangNational Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
Yu-Chao LinDepartment of Respiratory Therapy, China Medical University Hospital, Taichung, Taiwan.
Te-Chun HsiaDepartment of Respiratory Therapy, China Medical University Hospital, Taichung, Taiwan.
Hsing-Chun HsiehDepartment of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Jia-Syuan WuDepartment of Pharmacy, Chi-Mei Medical Center, Tainan, Taiwan.
Chi-Pei ChangDepartment of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan.
Yin-Hsun FengDivision of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan.
Peng-Chan LinDepartment of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Ping-Chih HsuDivision of Thoracic Medicine, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Huey-En TzengDivision of Hematology and Oncology, Department of Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
Shu-Chen ChienDepartment of Clinical Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Wei-Chiao ChangSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Chih-Cheng ChangDepartment of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Hsuan-Chia YangGraduate Institute of Biomedical Informatics, College of Medical Science & Technology, Taipei Medical University, Taipei, Taiwan.
Chueh Ming LeeDepartment of Family Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Christine Y LuDepartment of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, United States.
National Cheng Kung University Hospital · TWTaipei Medical University · TWChi Mei Medical Center · TWChina Medical University · TWHarvard University · USLinkou Chang Gung Memorial Hospital · TWMing Chuan University · TWNational Cheng Kung University · TWNational Health Research Institutes · TWTaipei Medical University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) have been approved to treat patients with various cancer types, including lung cancer, in many countries. This study aims to investigate the effectiveness and safety of ICIs under different treatment conditions of non-small cell lung cancer patients. A population-based retrospective cohort study was conducted using the electronic health records of three medical centers in Taiwan. From January 01, 2016, to November 30, 2018, a total of 91 ICIs and 300 traditional chemotherapy users who had undergone stage III and IV lung cancer treatment were included in the study. We performed the randomized matched pair design by selecting a Chemotherapy subject for each ICI patient in the sample population. All subjects were monitored from the date of taking ICIs or chemotherapy drugs until the event of death, loss to follow-up, or were occurred with any defined adverse events. Kaplan-Meier estimators and cox proportional hazard regression models were used to compute the overall survival, efficacy, and safety of the ICIs group. The median overall survival (OS) in the ICI and Chemo groups after matching was 11.2 months and 10.5 months, respectively. However, the results showed no significant OS differences between ICIs and chemo groups for both before and after matching (HR,1.30; 95%CI, 0.68-2.46; p=0.428 before matching and HR,0.96; 95CI%, 0.64-1.44; p=0.838 after matching). We observed that with the higher amount of PD-L1, the length of the patients' overall survival was (positive

Indexed as

effectivenessimmune checkpoint inhibitors (ICI)non-small-cell lung cancer (NSCLA)observational studyTaiwan

Identifiers

PMID34307141
PMCPMC8293991
OpenAlexW3179155092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.